Workflow
CLIP
icon
Search documents
“巴别鱼”梦想落地 “深圳造”AI耳机崛起
今年初,《深圳市加快推进人工智能终端产业发展行动计划(2025—2026年)》(简称《行动计划》) 中提出,到2026年深圳全市人工智能终端产业规模达8000亿元以上、力争1万亿元,在智能眼镜、智能 手表、智能耳机、AR/VR设备等细分赛道推出一系列人工智能标杆产品。这也是抢跑智能耳机终端市 场上,深圳再次先声夺人的鲜明痕迹。 "巴别鱼"如雨后春笋般涌现 1979年,道格拉斯·亚当斯写的《银河系漫游指南》出版,被无数科幻迷奉为圭臬。书中提到了神奇生 物"巴别鱼",只要放进耳朵,它就能自动翻译所有的语言,实现即时语言翻译。 近期,在一场比赛的聚光灯下,AI与人类译员的同传对决进入白热化。 当记分牌定格在1170:1062,深圳时空壶的W4 Pro AI同传耳机以破千分的优势胜出——这款搭载40种语 言、93种口音的AI同传耳机,正将跨语言对话的延迟压缩至3—5秒。 这场比赛恰似一面棱镜,折射出深圳智能耳机军团的技术突围。曾经以代工为标签的耳机企业,如今在 AI浪潮中集体转身:既有以冠旭电子、韶音科技、漫步者、智创一切、万魔声学等企业为代表的音频 品牌,也有华为、时空壶等互联网大厂和数码科技企业的入局,更有中科蓝 ...
斩获NASA订单的“登月新星”Firefly(FLY.US)递交IPO申请 欲登陆纳斯达克
Zhi Tong Cai Jing· 2025-07-12 04:23
Firefly Aerospace 是一家位于德州奥斯汀郊区Cedar Park的民营航空航天公司,主营小-中型运载火箭 (Alpha、与诺格共研的 Eclipse/Antares 330)、月球着陆器(Blue Ghost 系列)与轨道航天拖车(Elytra)等"端 到端"发射-月面-在轨服务;其目标市场主要是 1-10 吨载荷区间以及 NASA CLPS 月球任务。Firefly 最初 成立于 2014 年,经过2017年重组后专攻"中小型商用发射+深空货运"赛道 一名来自Firefly的发言人表示,此次发行股票数量和定价区间尚未正式确定。 Blue Ghost 之后下一跳——Firefly 带着 NASA "登月计划"订单赴纳斯达克上市。今年3月,Firefly所推 出的名为"蓝幽灵"(Blue Ghost)航天器成功着陆月球,成为史上第二个完成此壮举的大型商业着陆器。 该任务的其中一部分由美国国家航空航天局 (NASA) 资助,系其自1972年以来重启载人登月计划的重要 一环。 去年11月,Firefly 完成由 RPM Ventures领投的 1.75亿美元融资,整体估值超过20亿美元;今年5月,美 ...
半年盘点|上半年45个创新医疗器械获批,国产设备向高端化迈进
Di Yi Cai Jing· 2025-07-10 04:53
今年上半年,我国获批的创新医疗器械数量再创新高,国家药监局出台了优化全生命周期监管,支持高 端医疗器械创新发展的10项举措,包括心脏脉冲电场消融仪、心脏三尖瓣器械、血管内超声(IVUS) 导管等技术集成度高、研发难度大的创新医疗器械获批上市。 AI医疗器械、医疗机器人、植入式医疗器械等技术集成度高,属于高端医疗器械的典型产品,是塑造 医疗器械新质生产力的关键。 据国家药监局最新统计数据,我国今年上半年批准创新药43个,创新医疗器械45个,同比分别增长59% 和87%,改革政策红利正在转化为产业发展动力。 毕马威中国医疗健康和生命科学行业税务主管合伙人肖鑫在近日举办的毕马威首届健康科技50报告发布 会上指出:"AI医疗器械、医疗机器人、植入式医疗器械等技术集成度高,属于高端医疗器械的典型产 品,是塑造医疗器械新质生产力的关键。" 介入治疗迈向精准化 在这些获批的医疗器械中,本土医疗器械创新企业开始越来越多地崭露头角。近日,深圳北芯生命科技 自主创新研发的一款外周IVUS(血管内超声)导管获批三类医疗器械注册证,其打破了进口产品垄断 的局面,标志着中国外周血管精准介入的全新突破。 在传统外周血管介入治疗中,DSA ...
Lightning Round With Microsoft CEO Satya Nadella #tech #shorts
Bloomberg Television· 2025-07-09 23:00
Microsoft's biggest hit, Windows. Biggest miss, Clippy. It was just ahead of its time. It was just ahead of its time.It's back again. Biggest surprise. The biggest surprise was maybe maybe this OpenAI chat GPT having a chat interface become a hit was a real surprise.The concept of a chatbot isn't new. They tried before with Clippy, Cortana, and Tay, the bot that had to be shut down 16 hours after launch. Soon Tay was ranting about Hitler, but ChachiBT was a massive success, giving Microsoft a surprise jump ...
Should You Buy Abbott Stock At $135?
Forbes· 2025-07-09 10:35
CANADA - 2025/04/03: In this photo illustration, the Abbott Laboratories logo is seen displayed on a ... More smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)SOPA Images/LightRocket via Getty Images Abbott Laboratories (NYSE:ABT) has greatly exceeded the broader S&P 500 index this year, with its stock price increasing by 18% compared to the S&P 500’s 6% rise. This strong performance is due to the company’s solid quarterly results and positive future forecasts ...
国内首款、全球第三!V型左心耳闭合系统获批上市
思宇MedTech· 2025-07-07 09:38
招商通知: 第三届全球手术机器人大会 # 研究背景 左心耳是心房颤动异位激动和左心房血栓的重要来源,隔绝左心耳有助于减少脑卒中发生和血栓形成。 Atricure 是全球最早进入该领域的公司, 2010 年首款产品 AtriClip 经 FDA 批准在美国上市,迄今在全 球植入超过 65 万例 ,是目前 全球应用最多的左心耳闭合器。 2023 年底, 美敦力 的 Penditure 经 FDA 批准在美国上市,是 全球第 2 款一端开口的左心耳闭合器械 。 领健医疗 的 V-Clip ® 是 全球第 3 款获批的一端开口的左心耳闭合器械 。 V-Clip ® 作为 我国首个、全球第 3 款 问世的 V 型单端开口闭合夹式系统 ,其突破性结构设计显著优化 了左心耳的捕获与闭合效果,有效攻克了传统封堵器械因形态匹配问题产生的残余渗漏难题。该系统兼容 心脏开胸手术及微创入路,实施左心耳夹闭后,可大幅削减源自心脏的卒中风险,并降低患者对抗凝药物 的长期需求 。 心未来 近日, 北京领健医疗科技有限公司 (简称" 领健医疗 ")自主研发的 国内首款V型左心耳闭合系统V- Clip ® 正式获得NMPA 批准上市(国械注准 ...
2 Dividend Stocks to Buy for Decades of Passive Income
The Motley Fool· 2025-07-06 12:45
AbbVie - AbbVie is a pharmaceutical leader with a strong portfolio, particularly in immunology with products Skyrizi and Rinvoq, achieving a revenue increase of 8.4% year-over-year to $13.3 billion in Q1, with adjusted earnings per share at $2.46, a 6.5% increase [3][4] - Skyrizi generated $3.4 billion in sales, a 70.5% year-over-year increase, while Rinvoq's revenue was $1.7 billion, up 57.2% year-over-year; management forecasts combined annual sales exceeding $31 billion by 2027, significantly higher than the previous year's $17.7 billion [4][5] - AbbVie has a deep pipeline with approximately 90 products in development, allowing it to navigate patent cliffs and maintain long-term success [5][7] - AbbVie has increased its dividends by 310% since 2013 and has a track record of 53 consecutive years of payout increases, indicating strong potential for sustained passive income [8] Abbott Laboratories - Abbott Laboratories is a leader in the medical device space, with a diversified operation across diagnostics, pharmaceuticals, and nutrition, which helps mitigate challenges in specific segments [9][10] - The diabetes care segment, particularly the FreeStyle Libre continuous glucose monitoring system, has been a significant growth driver, becoming the most successful medical device in history in terms of dollar sales [11][12] - Abbott has increased its dividends by almost 146% over the past decade, reinforcing its reputation as a Dividend King and indicating a strong foundation for long-term dividend growth [13]
Life Beyond Earth: Science Fiction or Reality? | Anezina Solomonidou | TEDxPatras
TEDx Talks· 2025-07-01 15:56
[Music] [Applause] Anybody here a fan of Star Wars, Interstellar, Men in Black, X-Files? I thought so. Very good audience. Thank you. Is life beyond Earth a story we tell ourselves? Science fiction or it could be part of our reality just beyond our instruments and understanding. Imagine we are all now sitting in a spaceship as we do every morning. Right? For those of you who haven't done so yet, please fasten your seat belts. The countdown is about to begin. Imagine where would you like to go and input your ...
AI一眼认出95万物种,还能分辨雄雌老幼,2亿生物图像炼成“生命视觉”大模型
量子位· 2025-06-29 05:34
BIOCLIP 2团队 投稿 量子位 | 公众号 QbitAI 让AI看懂 95万物种 ,并自己悟出生态关系与个体差异! 而更令人惊喜的是,即使 在训练过程中没有相应监督信号 ,BioCLIP 2还在栖息地识别、植物疾病识别等5个非物种任务中给出了远超 DINOv2的准确率。 BioCLIP 2在大规模训练中获取了物种之外的涌现的生物学理解: 以下是论文详情: 把"生命之树"搬进显存 大语言/视觉模型的"涌现"告诉我们: 规模+结构化监督=意料之外的能力 。 然而,生物多样性研究领域一直没有见到一个具有涌现属性的视觉语义基座。BIOCLIP把CLIP的多模态对齐搬到物种上,利用〔界-门-纲-目- 科-属-种〕+学名+常用名的多粒度文本提供层级监督。在此基础之上,研究团队提出一个问题: 如果把层级对比学习从1千万张图像直接推到2亿,会不会学出 超越"物种标签" 的生物学知识? BIOCLIP 2正是这一实验的答案。 为了实现这一目标,研究团队从GBIF、EOL、BIOSCAN-5M、FathomNet等 4 大平台收集了2.14亿生物图像,提出了TreeOfLife-200M数 据集。该数据集包含95.2万个不 ...
Got $500? 2 Healthcare Stocks to Buy and Hold Forever
The Motley Fool· 2025-06-28 09:49
Core Viewpoint - The healthcare sector is positioned as a strong long-term investment opportunity, with a focus on companies that have shown adaptability and are well-prepared for future challenges [2]. Group 1: Abbott Laboratories - Abbott Laboratories, founded in 1888, has a market capitalization of $240 billion and offers diverse healthcare products across multiple sectors [4]. - The company is a leader in medical devices, diagnostics, nutritional products, and established pharmaceuticals, with notable products like the MitraClip and FreeStyle Libre [5][6]. - Abbott anticipates an 8% year-over-year revenue growth in 2025 and continues to innovate, recently receiving the European CE Mark for the Volt PFA System [7][8]. - Abbott has a strong dividend history, having increased its dividend for 53 consecutive years [8]. Group 2: AbbVie - AbbVie, spun off from Abbott in 2013, has a market capitalization of approximately $328 billion and generated $56.3 billion in sales last year [9][10]. - The company has successfully navigated the loss of U.S. exclusivity for its top product, Humira, by investing in R&D and acquisitions, leading to a robust product pipeline [11]. - AbbVie’s successors to Humira, Rinvoq and Skyrizi, are projected to generate combined sales of $31 billion by 2027, surpassing Humira's peak sales [12]. - AbbVie has increased its dividend by a cumulative 310% since its spin-off, with a forward dividend yield of 3.51% [12]. - The stock is considered relatively inexpensive, trading at 15.2 times forward earnings, with growth potential from new products [13].